A Tar Heel for life - The University of North Carolina at Chapel Hill
5 days ago • Google News
Tarsus Pharmaceuticals Inc (TARS)
US$ 41.46-6.2%
Price Chart
Key Statistics
Market Cap
$ 1.73B
P/E Ratio
0.00
Revenue (TTM)
$ 233.67M
Volume
1.7M
52W High
$ 57.28
52W Low
$ 20.08
Dividend Yield
0.00%
Beta
0.84
Technicals
50-Day MA
43.085
200-Day MA
45.8914
52 Week High
57.28
52 Week Low
20.0818
About TARS
Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for eye care in the United States.
Employees
323
Headquarters
Irvine, CA
CEO
Dr. Bobak R. Azamian M.D.
Latest News
Embodied AI startup TARS completes $122 million angel+ funding round: report - TechNode
2 days ago • Google News
Ferrie: Corn Growers are on High Alert for Tar Spot - AgWeb
Yesterday • Google News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg